share_log

Day One Biopharmaceutical Analyst Ratings

Day One Biopharmaceutical Analyst Ratings

第一天生物製藥分析師評級
Benzinga Analyst Ratings ·  2023/02/03 05:13
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating
02/03/2023 — Oppenheimer Initiates Coverage On → Perform
01/09/2023 185.06% Goldman Sachs $45 → $62 Maintains Buy
01/09/2023 106.9% Piper Sandler $40 → $45 Maintains Overweight
01/09/2023 106.9% HC Wainwright & Co. $35 → $45 Maintains Buy
12/15/2022 60.92% HC Wainwright & Co. → $35 Initiates Coverage On → Buy
12/14/2022 83.91% Needham → $40 Initiates Coverage On → Buy
12/05/2022 106.9% Goldman Sachs → $45 Initiates Coverage On → Buy
12/01/2022 56.32% B of A Securities → $34 Initiates Coverage On → Buy
06/21/2022 83.91% Piper Sandler $35 → $40 Maintains Overweight
06/14/2022 60.92% Wedbush $32 → $35 Maintains Outperform
06/21/2021 — Cowen & Co. Initiates Coverage On → Outperform
06/21/2021 37.93% Wedbush → $30 Initiates Coverage On → Outperform
06/21/2021 74.71% JP Morgan → $38 Initiates Coverage On → Overweight
06/21/2021 102.3% Piper Sandler → $44 Initiates Coverage On → Overweight
日期 上行/下行 分析公司 目標價格變動 評級變動 之前/當前的評級
02/03/2023 — 奧本海默 啓動覆蓋範圍開啓 → 表演
01/09/2023 185.06% 高盛 45 美元 → 62 美元 維護 買
01/09/2023 106.9% 派珀·桑德勒 40 美元 → 45 美元 維護 超重
01/09/2023 106.9% HC Wainwright & Co. 35 美元 → 45 美元 維護 買
2022 年 12 月 15 日 60.92% HC Wainwright & Co. → 35 美元 啓動覆蓋範圍開啓 → 購買
2022 年 12 月 14 日 83.91% 尼德姆 → 40 美元 啓動覆蓋範圍開啓 → 購買
12/05/2022 106.9% 高盛 → 45 美元 啓動覆蓋範圍開啓 → 購買
2022 年 1 月 12 日 56.32% B of A 類證券 → 34 美元 啓動覆蓋範圍開啓 → 購買
2022 年 6 月 21 日 83.91% 派珀·桑德勒 35 美元 → 40 美元 維護 超重
06/14/2022 60.92% Wedbush 32 美元 → 35 美元 維護 跑贏大盤
06/21/2021 — Cowen & Co. 啓動覆蓋範圍開啓 → 跑贏大盤
06/21/2021 37.93% Wedbush → 30 美元 啓動覆蓋範圍開啓 → 跑贏大盤
06/21/2021 74.71% 摩根大通 → 38 美元 啓動覆蓋範圍開啓 → 超重
06/21/2021 102.3% 派珀·桑德勒 → 44 美元 啓動覆蓋範圍開啓 → 超重

What is the target price for Day One Biopharmaceutical (DAWN)?

Day One Biopharmaceutical（DAWN）的目標價格是多少？

The latest price target for Day One Biopharmaceutical (NASDAQ: DAWN) was reported by Oppenheimer on February 3, 2023. The analyst firm set a price target for $0.00 expecting DAWN to fall to within 12 months (a possible -100.00% downside). 10 analyst firms have reported ratings in the last year.

奧本海默於2023年2月3日公佈了第一天生物製藥（納斯達克股票代碼：DAWN）的最新目標股價。該分析公司將目標股價定爲0.00美元，預計DAWN將在12個月內跌至12個月內（可能下跌-100.00％）。去年有10家分析公司公佈了評級。

What is the most recent analyst rating for Day One Biopharmaceutical (DAWN)?

Day One Biopharmaceutical（DAWN）的最新分析師評級是多少？

The latest analyst rating for Day One Biopharmaceutical (NASDAQ: DAWN) was provided by Oppenheimer, and Day One Biopharmaceutical initiated their perform rating.

第一天生物製藥（納斯達克股票代碼：DAWN）的最新分析師評級由奧本海默提供，第一天生物製藥啓動了其業績評級。

When is the next analyst rating going to be posted or updated for Day One Biopharmaceutical (DAWN)?

Day One Biopharmaceutical（DAWN）的下一份分析師評級何時發佈或更新？

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Day One Biopharmaceutical, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Day One Biopharmaceutical was filed on February 3, 2023 so you should expect the next rating to be made available sometime around February 3, 2024.

分析師在進行了廣泛的研究後得出了股票評級，其中包括瀏覽公開財務報表，與第一天生物製藥公司的高管和客戶交談，以及聽取業績電話會議。大多數分析師每三個月做一次這樣的評級，因此每家公司每年應該獲得4次評級。第一天生物製藥的最新評級是在2023年2月3日公佈的，因此您應該預計下一個評級將在2024年2月3日左右公佈。

Is the Analyst Rating Day One Biopharmaceutical (DAWN) correct?

分析師對第一天生物製藥（DAWN）的評級是否正確？

While ratings are subjective and will change, the latest Day One Biopharmaceutical (DAWN) rating was a initiated with a price target of $0.00 to $0.00. The current price Day One Biopharmaceutical (DAWN) is trading at is $21.75, which is out of the analyst's predicted range.

儘管評級是主觀的，並且會發生變化，但最新的第一天生物製藥（DAWN）評級最初設定爲0.00美元至0.00美元。目前第一天生物製藥（DAWN）的交易價格爲21.75美元，超出了分析師的預期區間。

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論